Antimicrobials

#Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Drug resistance

PACE launches new funding for antimicrobial drug development

PACE, one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic development, has launched its third round of funding to support innovative projects.  The initiative has announced £6 million ($8 million) in funding for antibacterial treatment innovations, aiming to tackle resistant bacterial infections and… Read More

#News

Klebsiella pneumoniae
#Antibiotics #Antimicrobials #Bacteria #Ritsumeikan University

Microbial discovery opens new doors to targeted antibiotics

Understanding the precise mechanism behind bacterial cell division can help in the development of targeted ways to inhibit bacterial proliferation.  To this end, researchers in Japan have explored the structure and molecular basis of the interaction between bacterial cell division-associated proteins FtsZ and ZapA.  Cell… Read More

#Editor's Choice #News

Patient taking antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobials #Bacteria #FDA #GSK #Urinary

New class of oral antibiotics for uUTIs gets FDA green light

The US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40kg) with uncomplicated urinary tract infections (uUTIs).  It is approved to treat infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex,… Read More

#News #Regulatory

Bacteria Citrobacter
#antibiotic #Antimicrobials #Artificial intelligence (AI) #Funding #Oxford Drug Design #Urinary

Oxford Drug Design awarded £1m to progress uUTI treatment

Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy).  In the UK, there were over 1.8 million hospital admissions involving UTIs between 2018-19 and 2022-23, with the condition being responsible for… Read More

#Business & Investment #News

Thermo Fisher Scientific
#Antimicrobial resistance (AMR) #Antimicrobials #Bacteria #Webinar

Structural advances in multidrug-resistant Acinetobacter baumannii

In a recent DDW event, sponsored by Thermo Fisher Scientific, Daniel J Klein, Senior Director of Protein and Structural Chemistry at Merck and Co discussed the current advancements taking place in antibiotic drug discovery. Klein spoke about how structural biology tools such as cryoelectron microscopy and X-ray crystallography are being used… Read More

#Exclusive Content

Bacteria
#Antimicrobials #Centauri Therapeutics #Funding #Immunotherapy

Centauri awarded £1m for immunotherapeutic technology

Immunotherapy developer Centauri Therapeutics has been awarded a £1 ($1.2) million grant by Pathways to Antimicrobial Clinical Efficacy (PACE), an initiative focused on early-stage antimicrobial drug and diagnostic discovery.   The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting gram-negative bacteria including multi-drug resistant (MDR)… Read More

#Business & Investment #News

#Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials

AMR: Steps in the right direction

News that the UK is supporting two new initiatives to help further the development of antimicrobials alongside other solutions to tackle resistant infections is welcome news for a sector that has, in recent years, struggled to attract the funding and attention it deserves.  The Pathways to Antimicrobial Clinical Efficacy (PACE) initiative… Read More

#Exclusive Content #Opinion

Petri dish used for bacterial research
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Funding

£30m initiative will support early-stage antimicrobial development

A partnership has been set up to promote the development of new treatments to tackle the global threat of antimicrobial resistance (AMR). Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 ($36) million initiative… Read More

#News #Trending News

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News

Scientists in laboratory
#Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Collaboration #Cresset Discovery #Partnership #Screening

Virtual screening partners to find new antimicrobial drugs

Cresset Discovery and the University of Exeter have entered a collaboration to discovery novel antimicrobial drugs.  Cresset Discovery will use virtual screening to identify promising new candidates, building on research led by Dr Stefano Pagliara.  Virtual screening enables chemists to explore new chemical space, discover… Read More

#News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials

World Antimicrobial Awareness Week: Antibiotics in the news 

For World Antimicrobial Awareness Week (18-24 November), DDW’s Diana Spencer provides an overview of the latest news in antimicrobial resistance and drug discovery.  1. New class of antibiotics for TB A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of… Read More

#Exclusive Content #News #Trending News

Pseudomonas aeruginosa
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Gut microbiome

How antibiotic resistant gut bacteria cause lung infections

An Oxford University study has provided the first evidence that antibiotic resistant bacteria can travel from the gut to the lung, increasing the risk of deadly infections.  The findings coincide with World Antimicrobial Awareness Week and shed light on how antimicrobial resistance (AMR) arises and persists.  … Read More

#News #Trending News

Antibiotics
#Antimicrobial resistance (AMR) #Antimicrobials #National Institute for Health and Care Excellence (NICE)

Important milestone reached in UK’s AMR fight 

The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of two new antimicrobial drugs to be used as part of a subscription style model within the healthcare system.   NICE has evaluated cefiderocol and ceftazidime–avibactam as part of a project with… Read More

#News

Francis Crick Institute
#Antimicrobials #Microbiology #Molecular Biology

Research on drug tolerance revealed 

Research from the Francis Crick Institute has revealed a key mechanism that increases tolerance to drugs amongst microbial communities. The findings could help the development of more effective antifungal treatments.    Background  Antimicrobial drug resistance and tolerance occurs when bacteria, viruses, fungi or parasites no… Read More

#News

#Antimicrobials #Bioconvergence #Drug development #Immunology / Virology & Vaccines #mRNA

Bioconvergence: Future trends for biomedicine

Dr. Tom Knapman, Director of Strategic Brand at SCIEX, explains how bioconvergent advances will help to drive key health trends in the coming year. As we move into 2022, we will see more and more advances in bioconvergence – biological, physical, and computing technologies inspired by nature. We expect these… Read More

#Exclusive Content #News #Opinion #Trending News #Trends & Analysis

#Antibiotics #Antimicrobials #Collaboration

AMR Action Fund appointment will help with antibiotic development 

 The AMR Action Fund, a public-private partnership supporting the development of new antibiotics to address rising antimicrobial resistance (AMR), has appointed William (Bill) Burns as Board Chair.   Burns has worked in the pharmaceutical and life sciences industry throughout his life, providing invaluable experience for his role as… Read More

#News